TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: 20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <20nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <100nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <500nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Chai Tai Tianqing Pharmaceutical Group
US Patent
Chai Tai Tianqing Pharmaceutical Group
US Patent
Affinity DataIC50: <1.00E+4nMAssay Description:The specific operation was as follows: 2.5 μl of the compound diluted in a 3-fold gradient was added to a 384-well plate, followed by adding 5 &...More data for this Ligand-Target Pair